Roche, Takeda and Pfizer notch top scores among rare disease patient advocacy groups

[cafead]

via Rare disease patients are seeing pharma companies in a better light these days—thanks in part to the COVID-19 vaccine halo effect, according to PatientView's latest survey of 230 rare disease patient advocacy groups. However, while some companies are doing better than others, there’s still a need for more transparency, better pricing and more patient engagement overall.

article source